CoImmune, Inc. and Memorial Sloan Kettering Cancer Center entered a license and collaboration agreement to accelerate the adaptation of CoImmune’s proprietary allogeneic CAR-CIK technology platform to treat solid tumors.
Memorial Sloan Kettering Cancer Center researchers assessed patient satisfaction and preferences for telemedicine, finding that 45% of people with cancer preferred telemedicine, while 34% preferred office visits and 21% had no preference.
The European Commission approved Keytruda (pembrolizumab), an anti-PD-1 therapy, in combination with chemotherapy for the first-line treatment of locally recurrent unresectable or metastatic triple-negative breast cancer in adults whose tumors express PD-L1 (CPS ≥10) and who have not received prior chemotherapy for metastatic disease.
The European Commission approved Opdivo (nivolumab) in combination with fluoropyrimidine- and platinum-based combination chemotherapy for the first-line treatment of adult patients with HER2-negative advanced or metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma whose tumors express PD-L1 with a combined positive score ≥ 5.
Point32Health and Takeda Pharmaceuticals America, Inc. signed a risk-sharing agreement around Takeda’s Alunbrig (brigatinib), a potent and selective tyrosine kinase inhibitor that is approved for adult patients with anaplastic lymphoma kinase-positive metastatic non-small cell lung cancer as detected by an FDA-approved test.
Congress needs to increase the FY22 base budgets of NIH and NCI by $3.2 billion and $1.1 billion, respectively, over FY21 levels, the American Association for Cancer Research said in its 2021 Cancer Progress Report.
Kelly C. Goldsmith, a physician-scientist specializing in pediatric oncology, has been named co-leader of the Discovery and Developmental Therapeutics Program, one of four research programs within Winship Cancer Institute of Emory University.
Madhusmita Behera was named the first chief informatics and data officer of Winship Cancer Institute of Emory University.
Aman Chhabra was named the first chief business officer of Winship Cancer Institute of Emory University.
Lali Medina Kauwe, has been appointed as co-program leader of the Cancer Biology Program within Cedars-Sinai Cancer at the Samuel Oschin Comprehensive Cancer Institute.
